Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts
about
sameAs
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathwayModels of breast cancer: is merging human and animal models the future?Antiangiogenic mechanisms and factors in breast cancer treatmentClinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3Anti-angiogenic alternatives to VEGF blockadeRadiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple IntegrinsMechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiformeTumor cell migration in complex microenvironmentsSelective alpha-particle mediated depletion of tumor vasculature with vascular normalizationIn vitro models of cancer stem cells and clinical applicationsRNA-Binding Protein Musashi1 Is a Central Regulator of Adhesion Pathways in Glioblastoma.Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions.Identification of putative drug targets for human sperm-egg interaction defect using protein network approach.Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.In situ validation of VEGFR-2 and α v ß 3 integrin as targets for breast lesion characterization.Cancer and the tumor microenvironment: a review of an essential relationship.Integrin alpha(v)beta(3)-Targeted Cancer Therapy.Mesenchymal migration as a therapeutic target in glioblastoma.Small molecule alpha(v) integrin antagonists: novel anticancer agents.A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv "Click Chemistry" targeted to αvβ3 integrin for therapy.In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene.Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.A phase I study of continuous infusion cilengitide in patients with solid tumors.Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.Integrin targeted therapeutics.The alpha v integrin antagonists as novel anticancer agents: an update.Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapyCilengitide induces autophagy-mediated cell death in glioma cells.The therapeutic potential of novel antiangiogenic therapies.Integrins: roles in cancer development and as treatment targets.CLT1 targets angiogenic endothelium through CLIC1 and fibronectin.Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer(64)Cu-NODAGA-c(RGDyK) Is a Promising New Angiogenesis PET Tracer: Correlation between Tumor Uptake and Integrin α(V)β(3) Expression in Human Neuroendocrine Tumor XenograftsMatrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II.Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy.Gene expression profiling of the anti-glioma effect of Cilengitide.Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.Alpha-v integrins as therapeutic targets in oncology.
P2860
Q24647759-6FADDAA1-EC9B-412C-B2E4-B7DF6EBCB313Q24803657-8001469F-FA8D-4A65-9753-BFBCBF8FAF1DQ26751226-08E12025-AED8-4ABB-9B1F-38471594639BQ26771417-BB11A538-78F4-40CA-BA9E-07224B9FA4DEQ26775947-A3FA6F20-EACC-4A88-8B23-08017B129ACFQ26801806-FC06FFEA-FA64-40E5-85FB-8C13B536BFA5Q26999917-F651AB8C-7A02-47DF-9FF5-E29770C4DEFEQ27027489-8929BD0D-A3F9-4530-8A7E-1133EAF33F0FQ27303072-9CD68EAA-5C4E-4461-B530-BCFAA363A868Q28076101-D2447C2C-8F17-4ABF-9167-0BF7A183FAD6Q30316434-1491AF87-D507-453A-A5B2-196BC34B1AEBQ30487248-0CB84713-5714-4101-8470-4DFA684C00B2Q30658102-874BDA3F-33DB-4317-8284-E588E67701AEQ33301860-FBAFD6D3-CD24-4B0A-97FE-9B5D167FE4A2Q33687901-B9436670-17F4-4B2A-B98B-09105FA3A92EQ33806357-4CD83D44-6F63-4D04-B8FA-F93D816AD084Q33983773-E2AA48F5-8D09-4D1B-8D6C-2CA83773ED6CQ34002994-DF7F1A50-845D-4AA0-9F67-C28EDCAF1F70Q34074899-303E8508-16FC-4709-B8E5-A8FE3C1BAA0DQ34167014-8ACD1C53-CDE2-4A23-93C5-A49F557F577EQ34194326-81CACCF7-065D-4B2D-9D64-51FC28B93D3FQ34433546-AA5FBF5F-4C1E-4DDB-9EF2-A2586641BBEDQ34447986-60CFDE0C-7572-4D60-B703-38ADECEA888FQ34687225-5DBBC703-8FA4-4C7C-B66C-FC704499CC2EQ34841141-BEA59850-D510-4316-8918-C026FA607C42Q34912684-B5FBDB79-A616-425D-B063-DD77BF13590EQ35011900-84F5C804-6ACC-4D62-B31B-E39279AFB844Q35129076-6DD65F53-2EBA-42A6-B96D-9D23A82C834FQ35133418-57ABAB48-3844-4910-9580-EB5B99B451EBQ35143984-915D63AF-447F-48AB-AC8A-0F840E5EB1D2Q35647842-C662E14A-0BA2-4509-BB1F-7C12D2AB3930Q35872325-B1B73DBB-DF3F-4EC0-B116-7E6ACDA2B859Q36065429-232F2FFF-37F4-4249-B377-FF635BE50F93Q36311285-3EA55CA5-F219-49F5-8FF3-050B9D854667Q36377161-F9636762-6D37-422B-9555-550DF455405BQ36753402-EC96C205-BEC9-4394-8D3D-85B89D57A3B9Q36824282-11A0FC0E-26E2-49DE-9C7E-4EE7854C6D09Q36884277-48B0EF5D-CCA5-4C64-BBFB-F844707B757BQ36887446-2DDF279C-6682-4FE1-8039-36B3B3FDBB80Q37008623-2E8BF67C-160B-4DD0-8999-26AFC2BA5037
P2860
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@ast
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@en
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@nl
type
label
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@ast
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@en
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@nl
prefLabel
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@ast
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@en
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@nl
P2093
P3181
P356
P1433
P1476
Cilengitide targeting of alpha ...... is in breast cancer xenografts
@en
P2093
Gerald L DeNardo
Kathleen R Lamborn
Laird A Miers
Patricia A Burke
Sally J DeNardo
Siegfried Matzku
P304
P3181
P356
10.1089/CBR.2000.15.71
P407
P577
2002-08-01T00:00:00Z